CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.31
+0.05 (+0.95%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.26
Open5.25
Bid5.03 x 4000
Ask5.35 x 800
Day's Range5.10 - 5.33
52 Week Range1.85 - 5.68
Volume936,865
Avg. Volume1,625,627
Market Cap545.544M
Beta (3Y Monthly)2.39
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.58
Trade prices are not sourced from all markets
  • An Intrinsic Calculation For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Suggests It's 32% Undervalued
    Simply Wall St.17 hours ago

    An Intrinsic Calculation For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Suggests It's 32% Undervalued

    How far off is Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discou...

  • Catalyst (CPRX) Up 58.1% Since Last Earnings Report: Can It Continue?
    Zacks3 days ago

    Catalyst (CPRX) Up 58.1% Since Last Earnings Report: Can It Continue?

    Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Why Catalyst Pharmaceuticals, Inc. Soared in March
    Motley Fool16 days ago

    Why Catalyst Pharmaceuticals, Inc. Soared in March

    Catalyst's new orphan drug is off to a strong start.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool20 days ago

    3 Top Biotech Stocks to Buy Right Now

    These biotech stocks could have a lot of room to run.

  • Why Wall Street Is Bullish on Catalyst Pharmaceuticals
    Market Realist25 days ago

    Why Wall Street Is Bullish on Catalyst Pharmaceuticals

    What Analysts Think about These Generic Pharmaceutical Stocks(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect an upside potential of 62.21% for Catalyst Pharmaceuticals (CPRX) based on the

  • Thomson Reuters StreetEvents25 days ago

    Edited Transcript of CPRX earnings conference call or presentation 19-Mar-19 12:30pm GMT

    Q4 2018 Catalyst Pharmaceuticals Inc Earnings Call

  • 2 High-Growth Stocks I'd Buy Right Now
    Motley Fool26 days ago

    2 High-Growth Stocks I'd Buy Right Now

    Catalyst Pharmaceuticals and HEXO could both be on the verge of a long-tailed growth trend.

  • Why Catalyst Pharmaceuticals Stock Is Popping Today
    Motley Foollast month

    Why Catalyst Pharmaceuticals Stock Is Popping Today

    The drugmaker's Q4 earnings release was a big hit with investors.

  • Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse
    Zackslast month

    Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse

    Catalyst (CPRX) reports wider-than-expected loss in the fourth quarter of 2018.

  • Benzingalast month

    The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 18) AstraZeneca plc (NYSE: AZN )(received orphan drug ...

  • Associated Presslast month

    Catalyst: 4Q Earnings Snapshot

    On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 14 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

  • GlobeNewswirelast month

    Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

    CORAL GABLES, Fla., March 18, 2019 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative.

  • The Catalyst Pharmaceuticals (NASDAQ:CPRX) Share Price Has Gained 181%, So Why Not Pay It Some Attention?
    Simply Wall St.last month

    The Catalyst Pharmaceuticals (NASDAQ:CPRX) Share Price Has Gained 181%, So Why Not Pay It Some Attention?

    The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in aRead More...

  • GlobeNewswirelast month

    Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release fourth quarter and year end 2018 financial results after market close on Monday, March 18, 2019. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Tuesday, March 19, 2019 to discuss the financial results and to provide a corporate update. A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com.

  • Reuters2 months ago

    U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug

    U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters. The drug is now sold at a list price of $375,000 a year by Catalyst Pharmaceuticals Inc under the brand name Firdapse. The company received Food and Drug Administration approval for Firdapse in November, along with rights to sell it exclusively for several years under a designation granted to developers of treatments for rare diseases.

  • GlobeNewswire2 months ago

    Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its support of Rare Disease Day 2019. Taking place today, Rare Disease Day involves activities worldwide to raise awareness of rare diseases and their impact on patients’ lives among the general public and decision-makers in industry and government. “We are proud to support Rare Disease Day and recognize the importance of investment in medical research that is needed to improve the lives of patients who are afflicted with rare and ultra-rare diseases,” said Patrick J. McEnany, Chairman and CEO of Catalyst.

  • GlobeNewswire2 months ago

    Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the Treatment of Lambert-Eaton Myasthenic Syndrome

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the online publication in the Journal of Clinical Neuromuscular Disease of the results of its second Phase 3 clinical trial (LMS-003) evaluating Firdapse® (amifampridine phosphate) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). The positive topline results from this trial were previously announced, but the full results of safety, efficacy, and other clinical data are now available online.

  • Reuters2 months ago

    Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

    Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry. Sanders, a vocal critic of high drug prices, had written to Florida-based Catalyst earlier this month, asking it to justify its price for Firdapse, a medication for a rare neuromuscular disease that affects about one in 100,000 people in the United States. It was also one of the campaign promises made by President Donald Trump in the 2016 elections.

  • GlobeNewswire2 months ago

    Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders

    CORAL GABLES, Fla., Feb. 21, 2019 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative.

  • Reuters2 months ago

    Catalyst Pharma sees net price of drug, once free, topping $300,000

    Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts. The drug, Firdapse, is used to treat Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder. U.S. Senator Bernie Sanders sent a letter to Catalyst last week asking the company to justify its pricing.

  • American City Business Journals2 months ago

    Coral Gables company under fire for drug pricing says patient care is 'top priority'

    Coral Gables-based Catalyst Pharmaceuticals said patient care is its "top priority" after Sen. Bernie Sanders, I-Vermont, criticized the firm for its pricing of a medication that treats a rare autoimmune disorder. "Catalyst’s top priority is improving patient care in the [Lambert-Eaton Myasthenic Syndrome] community and potentially elsewhere within the neuromuscular community," Catalyst said in a statement provided to the South Florida Business Journal.

  • GlobeNewswire2 months ago

    Catalyst Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference

    CORAL GABLES, Fla., Feb. 05, 2019 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative.

  • Reuters2 months ago

    U.S. Senator Sanders asks why drug, once free, now costs $375k

    U.S. Senator Bernie Sanders sent a letter to Catalyst Pharmaceuticals on Monday asking it to justify its decision to charge $375,000 annually for a medication that for years has been available to patients for free. The drug, Firdapse, is used to treat Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder, according to the letter, made available to Reuters by the senator's office. The government is intensifying its scrutiny of the pharmaceutical industry and rising prescription drug prices, a top voter concern and a priority of President Donald Trump's administration.

  • What Kind Of Shareholders Own Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)?
    Simply Wall St.3 months ago

    What Kind Of Shareholders Own Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)?

    Every investor in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares Read More...